Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb27564 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb27564 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XmAb-564 (Primary)
  • Indications Atopic dermatitis; Autoimmune disorders; Psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors Xencor

    • Most Recent Events

    • 12 Mar 2024 Results assessing whether XmAb564 selectively induced Tregs that coexpressed high levels of FoxP3, CD25 as well as LAG3/41BB/ICOS/HLADR/Ki67 and induced peripheral elevations of IL-10, consistent with systemic immunosuppressive activity, presented at the American Academy of Dermatology annual Meeting 2024
    • 03 Jun 2023 Results assessing safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) for 30-45 days presented at the 24th Annual Congress of the European League Against Rheumatism
    • 08 May 2023 According to an Xencor media release, data from this study will be presented at the European Alliance of Associations for Rheumatology (EULAR) Congress in 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top